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Abstract
Background:  Cervical-vaginal fluid (CVF) plays an important role in the prevention of
gynecological infections, although little is known about the contribution of CVF proteins to the
immunity of the lower female genital tract. In order to analyze the protein composition of human
CVF, we used CVF samples that are routinely collected during colposcopy, but are usually
discarded. Since these samples are available in large quantities we aimed to analyze their usefulness
for proteomics experiments. The samples were analyzed using different prefractionation
techniques (ultrafiltration and C4(RP)-LC protein separation) followed by C18(RP)-LC peptide
separation and identification by MALDI-TOF-TOF mass spectrometry. To determine the
reproducibility of this proteomics platform we analyzed three technical replicates. Using spectral
counting, protein abundances were estimated in a semiquantitative way. We also compared the
results obtained in this study with those from previous studies derived from patients with different
physiological conditions in order to determine an overlapping protein set.
Results: In total, we were able to identify 339 proteins in human CVF of which 151 proteins were
not identified in any other proteomics study on human CVF so far. Those included antimicrobial
peptides, such as human beta-defensin 2 and cathelicidin, which were known to be present in CVF,
and endometrial proteins such as glycodelin and ribonucleoprotein A. Comparison of our results
with previously published data led to the identification of a common protein set of 136 proteins.
This overlapping protein set shows increased fractions of immunological and extracellular proteins,
confirming the extracellular immunological role of CVF.
Conclusion: We demonstrated here that CVF colposcopy samples can be used in proteomics
experiments and hence are applicable for biomarker discovery experiments. The delineation of an
overlapping set of proteins that is identified in most proteomics studies on CVF may help in the
description of a reference proteome when performing proteomics studies on human CVF.
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Background
The female lower genital tract (vagina and ectocervix) is
exposed to a large microbial pressure, whereby pathogens
can invade via the mucosa or the epithelial layer. These
microorganisms can cause infections and diseases which
can lead to preterm birth, increased susceptibility to sexu-
ally transmitted diseases, infertility and cancer[1,2]. How-
ever, despite the frequent contact with pathogenic
microorganisms, the incidence of infections is relatively
low, suggesting that the female genital tract has developed
numerous defense mechanisms against potential patho-
gens. Of these, the constant removal of adherent bacteria
by shedding epithelial cells and the hydration of the cer-
vical-vaginal mucosa by excretions from cervical and vag-
inal glands and by plasma transudate are believed to be
most effective, yet these mechanisms are only partially
understood. These actions lead to the formation of a bio-
logical fluid in the ectocervix and vaginal region, called
the cervical-vaginal fluid (CVF) [1-6]. In addition, the vag-
inal and ectocervical mucosa is covered by numerous
commensal bacteria, such as Lactobacillus spp., which pro-
duce organic acids and compete with exogenous bacteria
for nutrients[1,2,5,7-9]. The adaptive immunity of the
lower female genital tract mainly constitutes of T-lym-
phocytes present in the lamina propria of the cervix, Lang-
erhans cells in the cervicovaginal mucosa and plasma cells
in the close vicinity of submucosal glands producing
secretory immunoglobulin A (sIgA) and IgG[1,10].
Recently, Tang et al.[11] suggested the presence of neu-
trophils and eosinophils on the basis of neutrophil and
eosinophil granule secretion proteins, present in the
human cervical-vaginal fluid. The innate immunity of the
mucosa of the female lower genital tract has antimicrobial
proteins/peptides (AMPs) (e.g. defensins, lactoferrin,
cathelicidin, lysozyme, SLPI, etc.) as predominant effector
molecules, which are present in cervicovaginal mucosal
and glandular excretions (reviewed in[1]). Although
structurally diverse, they are often small (< 100 amino
acids), cationic and amphipathic molecules[12]. AMPs
exert antimicrobial activity by 1) sequestration of micro-
bial nutrients[13,14], 2) disruption of microbial struc-
tural proteins and membranes [14-16] and 3) preventing
microbial adhesion on the mucosa[14,17]. Aside from
these activities, they also have effects on the host's immu-
nity[12] and on the target cells of viruses and bacteria [18-
20].
It has been frequently demonstrated that proteomic anal-
ysis of body fluids can yield information for biomarker
discovery and treatment development[21]. CVF samples
are especially interesting in terms of gynecological diag-
nostics since these samples can easily be collected using
non-invasive methods. Although conventional biomark-
ers are often quantified in plasma samples, there are two
reasons why CVF samples are preferred over plasma sam-
ples in terms of gynecological biomarker discovery.
Firstly, since the volume of plasma (± 3 liters) is much
larger than e.g. vaginal washings (CVF + washing fluid = ±
50 ml) it could be expected that dilution of a (potential)
biomarker will be much lower in the latter fluid. Sec-
ondly, altered biomarker expression patterns in plasma
are often not very specific as they may be associated with
different pathologies because plasma comes in contact
with all organs of the body. In contrast, when using CVF
samples, it is expected that expression patterns will
directly correlate with gynecological pathologies[22].
The first large proteomics study on the CVF proteome was
performed by Gravett et al. on Rhesus monkeys[23]. In
addition, seven studies analyzed peptides and proteins
present in human CVF using antibody-independent pro-
teomics techniques[11,24-29]. The studies of Venkatara-
man et al.[29], which focused on the cationic protein and
peptide fraction, and Di Quinzio et al.[26], which used
2D-PAGE to analyze common spots of the obtained gels
from different CVF samples, were limited to the identifica-
tion of subfractions of the CVF proteome. The other five
studies attempted to catalogue the whole CVF-pro-
teome[11,24,25,27,28] but differed in patient physiology
(healthy, infected, pregnant, etc.) and sample prepara-
tion, separation and identification methods. Mutual com-
parison of these studies shows there is a large variation in
protein identifications. This is not surprising given the fact
that CVF is a body fluid that can be influenced by many
biological factors including menstruation, age, infection,
sexual intercourse, usage of contraceptives, pregnancy, etc.
Also, the different studies on human CVF used diverse
sample collection and analytical methods to analyze the
CVF proteome, which may contribute to the large varia-
tion. We therefore hypothesise that the CVF proteome
consists of 1) a fixed set of proteins ("core proteome")
which is usually present in the extracellular cervical-vagi-
nal region independent of the condition of the patient
and applied experimental setups and 2) a variable set of
proteins whose abundance is dependent on (combina-
tions of) several of the abovementioned physiological and
experimental factors. These arguments point to the CVF as
a highly variable body fluid where normalization will be
an absolute prerequisite in considering the use of these
samples for biomarker identification and for diagnosis/
follow-up of gynecological diseases.
To further explore the CVF proteome, we combined
C4(RP)-LC on protein level followed by C18(RP)-LC on
peptide level with MALDI-TOF-TOF mass spectrometry
for protein identification. The main goal of the study was
to further complete the protein list of the CVF proteome
by analyzing new types of samples (routinely collected
samples that are available in high quantities; see below)
rather than measuring variability. We noticed however
that one part of our protein list consisted of newly identi-
fied proteins, while another part comprised proteins thatProteome Science 2009, 7:17 http://www.proteomesci.com/content/7/1/17
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were frequently identified in previous studies. This last set
("overlapping protein set") could be considered as a sub-
set of the human CVF "core proteome".
Methods
Sample collection
Low-grade squamous intraepithelial lesions (LSIL) are con-
sidered to be a benign cytological effect of human papil-
loma virus (HPV) replication. However, since 20% of these
individuals progress to high-grade squamous intraepithe-
lial lesions (HSIL)[30], a stage that precedes cervical cancer,
these women are routinely checked for progression to HSIL
by colposcopy, a procedure that requires washing of the
vagina with 5% acetic acid. The lavage fluid is usually dis-
carded but was used by us since these samples are routinely
collected and hence are available in large quantities. As
such, we wished to examine whether they could serve other
diagnostic and/or proteomics purposes too (e.g. early diag-
nosis of cervical cancer). Therefore, CVF samples were col-
lected from seven women with LSIL at the department of
gynecology of the University Hospital of Antwerp (UZA).
All patients (37–45 years old) included in this study were
either in the first or second half of the menstrual cycle, but
were not menstruating at time of sample collection, were
not pregnant, did not use any contraceptive and had not
had sexual intercourse less than 48 hours prior to sample
collection. The cervicovagina was washed with 50 ml of 5%
acetic acid for 2 minutes, the lavage fluid containing the
CVF was collected (15–30 ml), immediately transported to
the laboratory and stored at -80°C. Patients agreed to par-
ticipate by written consent.
Sample preparation and ultrafiltration
Six samples were pooled (together sample A; 191 ml; 128
μg/ml) and one sample (sample B; 16 ml; 111 μg/ml) (fig.
1) was not pooled prior to analysis. Sample A was divided
into two fractions: A (not ultrafiltrated; 31 ml; 128 μg/ml)
and Af+r (which was later ultrafiltrated; 160 ml; 128 μg/ml).
In order to improve the recovery of the low molecular weight
fraction (LMWF) from human CVF during ultrafiltration,
acetonitril (ACN) was added to sample Af+r to a final con-
centration of 20%[31]. All samples (A, Af+r and B) were then
centrifuged for 150 minutes at 4°C at 10000 g to obtain a
clear pellet and the supernatant was collected. Sample Af+r
was then applied onto Centriplus® centrifugal filter devices
(Amicon, Millipore, Bedford, MA, USA) with a molecular
weight cut-off of 30 kDa and filtered according to the manu-
facturer's guidelines. Unfiltrated samples A and B, the filtrate
(sample Af; 108 ml; 18 μg/ml) and the retentate (sample Ar;
8 ml; 1780 μg/ml) of sample Af+r were lyophilized to near
dryness. Afterwards, sample A (0.5 ml; 7960 μg/ml) was
divided into three fractions (samples A1, A2 and A3) in order
to determine the technical variation of the used analytic LC-
MS platform. Protein concentrations were determined using
the Bradford method.
Reversed phase (C4)-LC protein fractionation
Samples A1-3, Af (0.5 ml; 3300 μg/ml), Ar (1.0 ml; 9133
μg/ml) and B (0.5 ml; 4910 μg/ml) were fractionated on
a RP Protein C4 VYDAC HPLC column (214TP5415; 4.6 ×
150 mm, particle size 5 μm; Alltech Associates Inc., Lok-
eren, Belgium) using a Waters™ 600S controller, a Waters™
626 pump and a Waters™ 996 PDA (Waters Corporation,
Milford, MA, USA). Solvent A was 0.1% TFA in water and
solvent B 0.1% TFA in ACN. 1 mg of protein was loaded
on the column and an ACN gradient was applied which
differed between samples. In all cases the flowrate used for
the chromatography was 1 ml/min. For unfiltrated sam-
ples A1-3, and B the following gradient was used: 5 min-
utes 3%B, 3%B to 60%B over 15 minutes, 60%B to
100%B over 2 minutes, 2 minutes 100%B and 100%B to
3%B over 3 minutes. For the sample Ar (which contained
the larger proteins): 4 minutes 3%B, 3%B to 25%B over 1
minute, 25%B to 60%B over 15 minutes, 60%B to 100%B
over 2 minutes, 2 minutes 100%B and 100%B to 3%B
over 3 minutes. For sample Af (which contained smaller
proteins): 5 minutes 3%B, 3%B to 40%B over 15 minutes,
40%B to 100%B over 3 minutes, 2 minutes 100%B and
100%B to 3%B over 3 minutes. In all cases, 16 fractions
were collected every 1.5 minutes from minute 3 to minute
27. Fractions were lyophilized to dryness and protein con-
tent of the fractions was determined based upon the chro-
matogram surface.
Overview of the different workflows used Figure 1
Overview of the different workflows used. 7 samples 
were divided over 3 experimental setups using different frac-
tionation techniques (ultrafiltration and reversed phase (C4)-
LC protein fractionation). All processes ended with a C18-LC 
separation on peptide level and MALDI-TOF-TOF MS/MS 
analysis.
Sample A Sample B Sample Af+r
7 patients
6 samples pooled 1 sample
Filtrate(Af) Retentate(Ar)
Reversed phase (C4)-LC protein fractionation
Trypsinisation of fractions
C18-LC separation of peptides
MALDI-TOF-TOF MS/MS analysis
Ultrafiltration
A1 A2 A3Proteome Science 2009, 7:17 http://www.proteomesci.com/content/7/1/17
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Sample digestion
All fractions were resuspended in 50 mM TRIS.HCl/6 M
urea/5 mm dithiothreitol/10% beta-mercaptoethanol pH
8.5 (25 μl/100 μg protein). Because a minimum amount
of material is required to perform a reproducible trypsin
digest, fraction 1 was pooled with fractions 10–14, result-
ing in 9 fractions for further analysis. Each fraction was
incubated for 1 h at 65°C for denaturation and reduction.
Samples were diluted with 50 mM TRIS.HCl/1 mM CaCl2
(75 μl/100 μg protein) and alkylated by adding 200 mM
iodoacetamide (10 μl/100  μg protein; 1 h at 21°C in
dark). Proteomics-grade modified trypsin (Roche, Man-
heim, Germany) was added in a 30:1 protein-to-enzyme
ratio and fractions were incubated for 18 h at 37°C. Diges-
tion was stopped by freezing (-80°C).
Microcapillar HPLC separation of peptides and MALDI-
target spotting
One dimensional peptide separations were performed on
an Agilent 1100 series Micro-Capillary HPLC system (Agi-
lent Technologies, Waldbronn, Germany). Digested frac-
tions from sample A1-3, Af, Ar and B were injected at a
flowrate of 6 μl/min using a Rheodyne (Cotati, CA, USA)
9725 manual injection valve, connected with the capillary
pump, on a Zorbax 300SB-C18 guard column (0.3 mm × 5
mm; particle size 5 μm; Agilent Technologies) serially
connected with a Zorbax 300SB-C18 analytical reverse-
phase column (0.3 mm × 150 mm; particle size 3.5 μm;
Agilent Technologies). The solvents used were 0.1% for-
mic acid (FA) in water (solvent A) and 0.1%FA/90%ACN
(solvent B). Columns were equilibrated with 3% solvent
B. Using the capillary pump, an ACN gradient was applied
(flowrate 6 μl/min unchanged over the chromatographic
run): 5% to 55% in 56.7 min, ramp to 90%B over 3.3
min, 90%B for 5 min, 85%B for 5 min and back to equil-
ibrating conditions after the end of the run. During the
chromatographic separation, 350 spots (800 nl/spot)
were collected on Opti-TOF® MALDI-targets (28 columns
× 25 rows; 700 spots; 2 runs/target) (part number:
1018469; Applied Biosystems, Inc., Foster City, CA, USA)
with an 8 second interval starting from minute 5 to
minute 51.7 of the run. Thereafter, matrix (5 mg/ml α-
cyanohydroxy cinnamic acid in 70% ACN; internal cali-
brant: 63 pmol/ml human [Glu1]-fibrinopeptide B) was
added to the collected spots using an external syringe
pump. A flow-rate of 6 μl/min was applied and matrix was
spotted with an 8 second interval (800 nl matrix/spot)
until all spots were covered with matrix.
MALDI-TOF-TOF analysis
Spots from samples A1-3, Af, Ar and B were analyzed
using an AB4800 proteomics analyzer (Applied Biosys-
tems) first by MALDI-TOF (reflectron mode; 25 × 20 laser-
shots per spot; mass-range: 700–2500 Da; laser intensity:
2500) and precursors with a signal-to-noise (S/N) ratio
above or equal to 35 were selected for MALDI-TOF-TOF
(MS/MS) analysis. A maximum of 50 unique precursors
per spot was selected for fragmentation, starting from the
precursor with the lowest S/N-ratio. Selected precursors
were ionized (25 × 20 lasershots per spot; laser intensity:
4000) and fragmented in a collision cell (1 kV collisions
(positive mode) with air).
Data analysis
Protein identification
Spectra obtained from the different samples (A1-3, Af, Ar
and B) were sent to the MASCOT search engine (version
2.1.03; http://www.matrixscience.com) using the GPS
Explorer Software (Applied Biosystems) and screened
against the Swissprot database specified for Homo sapiens
(version: Sprot_55.2). Carbamidomethylation of cystein
was entered as a fixed modification, while oxidation of
methionine was entered as a variable modification. Up to
two missed trypsin cleavages were tolerated. The mass tol-
erance for the precursors was 50 ppm and 0.25 Da for the
fragment ions. The MudPIT scoring algorithm was used.
Since proteins that are part of the LMWF often result in
only a few or one detectable tryptic peptide, protein iden-
tifications with one unique peptide were allowed and
accepted, however only under certain stringent condi-
tions. In general, only the top-ranking peptides (for more
information see http://www.matrixscience.com/
help_index.html) were used for identification, the differ-
ence between the calculated and experimental peptide-
mass had to be larger than -0.1 and less than 0.1 and the
obtained spectra, used for identification, had to fulfil the
criteria for high quality spectra (see below)[32]. Beside
those, additional criteria used were: 1) Proteins with a
MASCOT-score that corresponded with p-value < 0.01
were considered identified if there was at least one unique
peptide, used for the identification, with a peptide-score
above or equal to the threshold score and with a length of
at least 7 amino acids. 2) Protein identifications with a
MASCOT-score that corresponded with a p-value between
0.05–0.01 were manually validated. Here, peptides used
for identification were to meet the following criteria[32]:
peptides had to be at least 7 amino acids long, the pep-
tide-score had to be above or equal to the threshold score
and the spectra had to contain at least 3 consecutive b-
and/or y-ions. The partially identified sequences were
then submitted to "BLAST protein-protein" http://
www.ncbi.nih.gov/BLAST and screened against the Homo
sapiens  Swissprot database to see if this identification
matched the MASCOT-identification. All keratins were
removed from the list.
In order to analyze whether the applied identification
methodology described above was stringent enough, we
estimated the false discovery rate on the protein level
(FDR). Therefore, spectra were screened against a concate-
nated database consisting of the target Swissprot databaseProteome Science 2009, 7:17 http://www.proteomesci.com/content/7/1/17
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(Homo sapiens) and a shuffled (decoy) Swissprot database
(Homo sapiens). FDR was calculated as described: 2× false
positive identifications/(false positive identifications +
true positive identifications)[33]. In all cases, the FDR on
the protein level had to be less than 5% before we
assumed that the obtained results were trustworthy.
Functional and cellular component classification of proteins
Functional classification of proteins was achieved using a
multi-staged classification methodology based upon four
different databases: 1) The "PANTHER" classification sys-
tem http://www.pantherdb.org[34,35], 2) Gene Ontology
http://www.geneontology.org[36], 3) the "DAVID" data-
base http://david.abcc.ncifcrf.gov[37] and 4) Swissprot
(manual annotation of proteins not classified using the
other three databases). Proteins which remained unclassi-
fied after applying the four abovementioned tools were
placed in the "not determined" (ND) category. Classifica-
tion of proteins according to their cellular localization
was achieved using a similar method as used for the func-
tional classification, with the exception that the "PAN-
THER" classification system was not used. Again,
unclassified proteins were placed in the ND category.
Semiquantitative analysis of proteins
To semiquantitatively estimate the abundance of a protein
in a mixture, we determined the total count of MS/MS
spectra for each detected protein [38-41]. To correct the
determined spectral count for differences in protein size,
we normalized by dividing the number of counted spectra
through the number of predicted observable peptides [40-
42]. These observable peptides are obtained after in silico
trypsinization of the protein. However, due to some tech-
nical restrictions, not all theoretical tryptic peptides can be
identified. Therefore, the theoretical tryptic peptides were
filtered according to their mass (mass-range mass spec-
trometer: 700–2500 Da) and we estimated retention time
(C18(RP)-LC eluate collection window: from minute 5 to
51.7) using the "Sequence Specific Retention Calculator"
version 3.0[43]. We then calculated the Normalized Spec-
tral Abundance Factor (NSAF)[41], which is directly pro-
portional to the molar concentration, as follows
(equation 1):
Where SC is the number of spectral counts for protein k,
OP the number of observable peptides (after filtering) and
N the total number of proteins identified in one experi-
ment. For convenience we multiplied these NSAF-values
by a factor of 1000. We also calculated a "normalized
spectral count factor" (NSCF), which does not take into
account the number of observable peptides, and normal-
ized those data by dividing the number of spectral counts
for protein k  through the summation of the spectral
counts of all identified proteins N (equation 2).
Again, we multiplied these NSCF-values by a factor 1000
for convenience. This NSCF-value is directly proportional
to the mass concentration rather then molar concentra-
tion[44].
Comparison of the obtained data with previous studies 
using a relational database
For the comparison of the different proteomics studies on
CVF, a relational database was constructed in Microsoft®
Office Access 2003 around the data presented in the arti-
cles[11,23-29] and our study. Before creating the final
input lists for the database, we manually examined all
data sets and corrected for redundancies since we noticed
that in some cases the same proteins were entered more
than once or different proteins were identified by the
same set of peptides. Each study was entered in a table
containing a specific study number and the Swissprot
accession numbers of the identified proteins. These tables
were linked to a table with the study specifications and a
table with the corresponding protein descriptions. The lat-
ter was further linked with tables containing specific
details about the identified proteins (functional classifica-
tion, cellular component classification, MW, pI, etc.; addi-
tional file 1).
Results
Protein identification from human cervical-vaginal fluid
Since it is well described that usage of different fractiona-
tion techniques enhances the dynamic range of the exper-
imental setup and increases proteome coverage[45], we
analyzed the effect of the incorporation of an ultrafiltra-
tion (cut-off 30 kDa) step, prior to the C4(reversed-phase
(RP))-LC fractionation on the protein level, on the
number of protein identifications obtained (fig. 1). Every
experimental setup ended in C18(RP)-LC peptide separa-
tion and MALDI-TOF-TOF mass spectrometric analysis.
Table 1 shows the number of spectra collected during MS-
analysis of the different samples. Also shown is the
number of proteins identified by Mascot with a score cor-
responding to a p-value of < 0.05 (second column). A fur-
ther manual screening of this protein list was performed
since proteins often represented several isoforms or pro-
tein subsets that could not be identified on the unique
peptide level. Isoforms of a particular protein were only
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taken up in the final protein list when it was possible to
identify with a high degree of confidence the peptide
which contained the discriminating sequence. We also
noticed during this validation that many identifications
were based upon low scoring peptides which did not ful-
fill the criteria described in the Methods section (see
above) and hence were left out. The last column therefore
shows the number of proteins which were considered
identified after applying the manual data-analysis and
after removal of known contaminants such as keratins. As
can be seen, using these stringent criteria, about half of the
proteins from the original list passed this screening. We
believe this stringent screening is necessary in order to be
able to positively identify small proteins and peptides on
the base of only one unique peptide.
In order to estimate the FDR of the applied identification
methodology, spectra from each experimental setup were
screened against a concatenated database consisting of a
forward (target) Swissprot database and a shuffled
(decoy) database. FDR estimations were calculated as
described[33] and were as follows: 2.7% (sample A1),
2.0% (sample A2), 2.2% (sample A3), 2.0% (sample Af),
2.2% (sample Ar) and 1.4% (sample B).
Table 2 lists the number of proteins identified in the dif-
ferent experiments and shows the overlapping numbers.
All together, we were able to identify 339 proteins from
human CVF with high confidence. Complete lists of iden-
tifications and their corresponding score from the differ-
ent experiments are presented in the supporting
information (additional file 2). 151 (45%) out of those
339 proteins had not been identified in any other previ-
ous study (additional file 3).
We then classified the proteins according to the biological
process in which they exert their role and their cellular
localization. We noticed that CVF consists of a mixture of
proteins with a wide variety of functions. The largest cate-
gories are formed by proteins which have a function in
protein metabolism and modification (19%), immunity
and defense (13%), developmental process (9%) and sig-
nal transduction (9%). Aside from these, several smaller
functional categories were also represented (additional
file 4). Using the multi-staged classification process (see
Methods) we could reduce the unclassified category from
17% (PANTHER alone) to 2%. Classification according to
their cellular localization showed us that identified pro-
teins were most likely to be present in the cytoplasm
(26%), extracellular region (25%), membrane (12%) and
cytoskeleton (11%). The complete cellular component
classification is presented in additional file 5.
Analysis of the technical variation of the applied LC-MS 
platform
To determine the technical variation of the used LC-MS
platform, we analyzed a pool of CVF (sample A) in tripli-
cate. After centrifugation and lyophilization, sample A
was divided into three fractions (sample A1, A2 and A3)
which were separately analyzed in triplicate. The Venn-
diagram illustrating the number of proteins found in each
technical replicate and the overlap between the triplicates
are shown in figure 2. In total, 237 different proteins were
identified in the three technical replicates, of which 119
were common to all three replicates. To correctly calculate
the percentage of shared versus total number of identifica-
tions we made use of the calculation of Hattan et al[46].
that takes into account the redundancy of identifications.
The three technical replicates therefore yielded 526
(147+201+178) identifications of which 357 (3*119)
were found in all three replicates. This results in a ratio of
68% (357/526).
Estimation of protein abundance
We estimated protein abundances of the identified pro-
teins using the spectral counting method and calculated
the NSAF-value (equation 1). The spectral counting infor-
mation of all proteins identified in the different experi-
ments is given in the additional information (additional
file 6). The results show clearly that protein S100A9 is the
most abundant protein present in human CVF.
We next compared our spectral counting information
with results from other studies on human CVF[24,27]. In
Table 1: Overview of the number of spectra collected and MASCOT search results before and after manual data inspection. 
# spectra collected # proteins identified before
manual data-analysis
# proteins identified after 
manual data-analysis
Sample A1 6351 312 147
Sample A2 10514 424 201
Sample A3 9063 364 179
Sample Af 7630 194 85
Sample Ar 9711 329 164
Sample B 6880 210 129
For each sample the number of spectra collected (column 1), the number of proteins which were identified by Mascot with a score which 
corresponded with a p-value < 0.05, before (column 2) and after (column 3) our manual data analysis, are presented.Proteome Science 2009, 7:17 http://www.proteomesci.com/content/7/1/17
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order to achieve this, we selected from the common 119
proteins (see above), those which were also present in the
studies from Dasari et al.[24] and Pereira et al.[27]. This
resulted in 67 proteins. For a correct comparison, average
NSCF values over the three technical replicates for these
proteins were calculated after which proteins were ranked
according to their abundancy (1 = most abundant; 67 =
least abundant). Proteins were then sorted on the basis of
the ranking from Dasari et al. and plotted as protein (x-
axis) vs. rank (y-axis). After removal of six outliers, best-fit
plots were calculated showing very similar trends in all of
the three studies (fig. 3).
Delineation of an overlapping protein set that is shared by 
various CVF proteomics studies
Comparison of our results with those from others
[11,24,26-29] showed a very high variability in protein
identifications between different studies. However, we
reasoned that if one considers the CVF "core proteome" as
a set of proteins that is present in theoretically every CVF
sample, then these proteins must appear in the majority of
CVF proteomics studies, even when these studies make
use of samples originating from patients under different
physiological conditions. Although the determination of
the complete CVF "core proteome" lies beyond the scope
of this study, an overlapping protein set which is shared
by diverse proteomics studies and which is therefore irre-
spective of sampling and analytical methods as well as
patient physiology, may very well represent a subset of
this "core proteome" and hence may be a first step in
delineating it. We therefore constructed a relational data-
base (additional file 1) consisting of our data combined
with data from all proteomics studies on CVF[11,24-29].
Thus far, a total of 826 proteins were identified from the
CVF proteome (complete list, overlapping proteins (addi-
tional file 7), and functional (additional file 8) and cellu-
lar component (additional file 9) classification of those
proteins can be found in the additional information.
Using this database, we extracted an overlapping protein
set from the three most comprehensive studies[24,27,28]
(all with > 150 identifications) and our results (fig. 4). In
total, 136 proteins (listed in additional file 10 and 11)
were present in at least 3 out of 4 studies, of which 92 were
present in all four studies. As can be seen in table 3, these
studies made use of samples coming from patients with
different profiles. Moreover, the samples underwent vari-
ous experimental procedures, indicating that this overlap-
ping protein set can be identified, independent of patient
physiology or applied analytical methods.
We then compared the proportion (in percentage) of the
functional and cellular component categories from this
overlapping protein set (respectively fig. 5B and 6B) with
those from the total CVF proteome, consisting of all 826
proteins (respectively fig. 5A and 6A), and calculated the
fold change (increase/decrease) between these two sets
(fig. 5C and 6C). The calculation was done as follows: per-
centage of a specific category of the overlapping protein
set divided by the percentage of that category in the total
proteome. Hence, a fold change > 1 indicates an increase
of a particular category in the overlapping protein set.
Highly variable categories (i.e. categories consisting of
proteins which differ a lot between different studies) will
lead to a fold change < 1, since only a small fraction of this
category will be identified in more studies. Figure 5C
shows an increase of the "immunity and defense" and the
"developmental processes" category in the overlapping
protein set, whereas all other functional categories
decrease.
Similarly, figure 6C shows the fold change in cellular
localization classification. Here, two categories ("extracel-
lular region" and "cytoskeleton") were markedly
increased in the overlapping protein set.
Discussion
Evaluation of different experimental setups for human 
CVF proteomics analysis
In order to obtain a maximal coverage of the CVF pro-
teome, we evaluated the effect of enhanced sample frac-
tionation on identification yield (fig. 1).
Table 2: Overview of the number of proteins identified in the 
different experimental setups showing the interexperimental 
overlap.
S a m p l e :A 1A 2A 3 A 1 - 3 A fA rA f + rB
A1 147
A2 130 201
A3 126 152 178
A1-3 147 201 178 237
Af 48 53 50 55 85
Ar 87 103 93 109 49 164
Af+r 94 112 100 118 85 164 200
B 87 95 91 103 48 79 84 129
Overlap of protein identifications between three technical  replicates Figure 2
Overlap of protein identifications between three 
technical replicates.
Technical replicate 1 (147 ID’s) Technical replicate 2 (201 ID’s)
Technical replicate 3 (178 ID’s)
119
73 3
11 10 38
19Proteome Science 2009, 7:17 http://www.proteomesci.com/content/7/1/17
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An average of 175 proteins was identified in the three
technical replicates (samples A1-3; no ultrafiltration +
C4(RP)-LC). This number is lower than the 200 identifica-
tions obtained from samples Af+r (ultrafiltration +
C4(RP)-LC), suggesting that the setup with the highest
degree of prefractionation (sample Af+r) still results in the
largest number of identifications. However, although it
was expected that extended prefractionation drastically
reduces sample complexity resulting in an enhancement
of proteome coverage and dynamic range of the used
method[45], the effect of an additional ultrafiltration is
only modest. Moreover, filtrate (Af) and retentate (Ar)
showed a significant overlap (49 proteins), suggesting
that ultrafiltration does not result in a precise separation,
as also suggested in other studies[47]. Therefore, supple-
mentary prefractionation on the protein level, such as
SCX-LC or SDS-PAGE, may prove more useful, although
these procedures suffer from an increased workload and
sample consumption.
When comparing the pooled samples A1-3 (technical rep-
licates) with the single sample B (which was not part of
the pool; table 2), 80% of the proteins from sample B
were also found in samples A1-3. This preliminary com-
parison points to a significant overlap between samples
from different patients. Further studies with more samples
are required to ascertain this (Van Raemdonck et al., in
preparation).
Since 339 protein identifications is clearly above the aver-
age number as compared to previous publications, and
because a large fraction of these proteins is frequently
found in other studies too (see below), we conclude that
the samples resulting from the colposcopy of patients
with LSIL may well be used for proteomics studies, e.g. for
biomarker discovery.
Analysis of the technical variation of the applied LC-MS 
platform
119 identifications were found in all of the three technical
replicates (samples A1, A2 and A3), which is an overlap of
68% between these replicates. Moreover, 89% of all pep-
tides were used to identify these 119 overlapping proteins.
These results are very similar in terms of technical varia-
tion and reproducibility as compared to other studies
which analyzed technical replicates based on multidimen-
sional LC-MS proteome analysis platforms, such as those
from Liu et al.[44] and Shaw et al.[28] (respectively 60%
and 70% overlap between technical replicates).
Comparison of spectral counting information from different studies Figure 3
Comparison of spectral counting information from different studies.
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It has been stated that, for complex protein mixtures, a mul-
tidimensional chromatographic separation is reasonably
reproducible, whereas the acquisition of MS/MS spectra
(and therefore also the identification of proteins) shows
much less reproducibility[48]. This assumption was con-
firmed by the analysis of the reproducibility of our LC-sys-
tem based on the comparison of retention times derived
from 63 peaks extracted from the chromatograms of three
technical replicates. We determined an average coefficient
of variance of 0.56% meaning that the chromatography is
very reproducible. As such, these results suggest that the
largest variation of the platform can probably be found at
the level of the mass spectrometric analyses. We assume
that a certain degree of random selection of precursor-ions,
the masking of low abundant peptides by higher abundant
ones[44] and small day-to-day variations in sensitivity and
accuracy may result in variable MS/MS spectra influencing
the reproducibility of the platform[49].
Characterization of the CVF proteome
A substantial number of identifications concerned pro-
teins with a serine protease function (e.g. kallikrein-6/10/
11/13/14, transmembrane serine proteases 11D/11E, leu-
kocyte elastase and myeloblastin) and other proteases
(e.g. cathepsin G). Also, inhibitors of serine proteases
(serpin B3/B4/B12/B13, calpastatin, SLPI, alpha-1 antit-
rypsin, serine protease inhibitor Kazal-type 7/5, plasma
serine protease inhibitor), inhibitors of cystein proteases
(calpastatin, cystatin A/B) and inhibitors of other pro-
teases (SLPI, WAP four-disulfide core domain protein 2)
were found. Many of these serve an immunological func-
tion (beside other functions) and some are described to
originate from neutrophils (elastase, cathepsin G).
Indeed, the presence of polymorphonuclear leucocytes in
CVF was recently demonstrated by Tang et al.[11]. Other
immune peptides and proteins (e.g. defensins, lactoferrin,
immunoglobulins, azurocidin, myeloperoxidase, TLR-7,
Table 3: Overview of studies performed on human CVF. 
Study Samples Part of sample analyzed Separation method MS method
Venkataraman et al., 
2005[29]
Undiluted CVF collected in 
cup from healthy women 
(postmenarcheal, pre-
menopausal)
Cationic fraction 2D-PAGE 
(1D: AU-PAGE; 2D: 
Tricine- SDS-PAGE)
MALDI-TOF-TOF
Di Quinzio et al., 2007[26] Swabs from pregnant 
women 
(37 weeks gestation)
Only protein spots 
identified common to five 
gels
2D-PAGE (1stD: IEF; 2ndD 
SDS-PAGE) followed by 
RP-LC
MALDI-TOF or ESI-linear 
IT
Dasari et al., 2007[24] Swabs from pregnant 
women 
(18,5 weeks gestation as 
mean)
Whole CVF 1D-SDS-PAGE followed by 
offline 2D(SCX/RP)-LC
ESI-Q-TOF
Tang et al., 2007[11] Washings from clinically 
normal women; 7 washings 
from women infected with 
Candida spp.
Whole CVF 2D-PAGE (1stD: IEF; 2ndD 
SDS-PAGE)
MALDI-TOF-TOF
Shaw et al., 2007[28] Gauze from healthy 
women
Whole CVF 1D-SDS-PAGE or SCX-LC 
both followed by RP-LC
ESI-linear IT
Pereira et al., 2007[27] Swabs from pregnant 
women 
(15.8–35.9 weeks 
gestation)
Whole CVF 2D-DIGE or MudPIT(SCX/
RP)-LC
ESI-Q-TOF
Klein et al., 2008[25] Swabs from pregnant 
women 
(30.5 weeks gestation as 
mean)
Whole CVF RP-LC ESI-IT
This study Washings from HPV-
infected women
Whole CVF Ultrafiltration or C4-LC 
protein fractionation/C18-
LC peptide separation
MALDI-TOF-TOF
For each study the following information is presented: 1) the nature of the samples which were used in the study (sample collection method and 
patient physiology), 2) whether the study focused on a particular part of the sample or analyzed the whole CVF, 3) the methods used to separate 
proteins and peptides and 4) MS method used for analysis.Proteome Science 2009, 7:17 http://www.proteomesci.com/content/7/1/17
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IL-17 ...) were also identified of which cathelicidin (sam-
ple A1-3, Af+r and B) and human beta-defensin 2 (HBD-
2; sample A1-3 and B) were of special interest. These anti-
microbial peptides have not been identified in any other
proteomics study on CVF so far[11,24-29]. Frohm et al.
used immunohistochemistry to show that cathelicidin is
expressed by the squamous epithelium of the cervix and
vagina[50]. Also, the group of Valore et al. analyzed the
concentration of several AMP's in CVF using ELISA and
determined the concentration of HBD-2 (0.57 ± 0.13 μg/
ml)[5]. Remarkably, although the measured concentra-
tion of human neutrophil peptide (HNP; alpha-defensin)
(0.35 ± 0.07 μg/ml) was slightly lower than HBD-2[5],
almost every proteomics study on human CVF was able to
identify HNP, but not HBD-2[24,27-29], thereby raising
the question as to why it is so difficult to identify HBD in
CVF samples. We presume that the reason for this may be
found in the higher arginine and lysine content of the
cathelicidin propeptide (19%; one observable peptide)
and HBD-2 (18%; three observable peptides) compared
to HNP (12%; 5 observable peptides) which leaves, after
trypsinization, only very few peptides that are large
enough for identification by MS.
A large portion of the identified proteins, including
involucrin, small proline rich proteins, cystatin A and
desmosomal proteins, are components of the cornified
envelope, a protein/lipid structure situated just below the
epithelial cell membrane[51]. At the final stage of epithe-
lial cell differentiation, this envelope resides on the exte-
rior of the dead cornified cells, so that many of its
elements may come off and could be detected in the CVF.
This process is probably stimulated by the subsequent
changes in estrogen and progesterone levels during men-
struation, which causes cyclic histological changes in the
cervical-vaginal epithelium[52].
Of particular interest were some endometrial proteins
including glycodelin (picked up for the first time in CVF),
a protein involved in regulation of the uterine environ-
ment[53], and heterogeneous nuclear ribonucleoprotein
A which is thought to serve a role in the formation of spe-
cific myometrial proteins[54]. We also identified proteins
such as mucin 5B which is an important component of
secreted mucus[55] and carbonic anhydrase 1/2 which is
involved in the formation of aqueous humor[56].
25% of the identified proteins were present in the extra-
cellular compartment, which was to be expected since
samples concerned an extracellular fluid. By comparison,
the studies of Dasari et al.[24], Pereira et al.[27] and Tang
et al.[11] identified about 39% extracellular proteins. All
of the abovementioned studies[11,24,27], including ours,
removed cells from their samples by centrifugation. The
use of 5% acetic acid as colposcopy washing buffer in our
study may have caused additional cellular lysis before cen-
trifugation of the samples. Nonetheless, in absolute num-
bers, 83 proteins were classified in the extracellular region
which is more than in any of the three abovementioned
studies[11,24,27] (respectively 22, 58 and 79). We there-
fore conclude that the colposcopy samples have the
intrinsic disadvantage of increased cellular lysis but this is
compensated for by the proteomics platform described
here.
In general, intracellular proteins are abundantly identified
in every study. This may have different reasons. A certain
number of lysed cells may always be present in CVF
because of the natural loss of epithelial cells in the course
of the menstrual cycle[52]. Also, all patients were infected
with HPV which leads to a weakening of the cornified
envelope resulting in fragile cells[57,58] that are more
easily lysed upon mechanical stress. Intracellular proteins
may also have an extracellular function, such as histones
(which were also identified in this study) that are secreted
or are part of the "neutrophil extracellular traps" (long
extensions built out of chromatine and elastase and which
are able to bind and inhibit bacteria and fungi [59-61]).
Furthermore, it has been shown that exosomes (nanoves-
icles which are secreted and carry MHC and adhesion
molecules on their surfaces and contain cytosolic enzymes
and proteins) can be secreted by epithelial cells and B
cells, although this has not yet been described for the cer-
vical-vaginal mucosa[62,63]. Finally, intracellular pro-
teins may be actively secreted to fulfill an as yet unknown
extracellular physiological function.
Estimation of protein abundance
We used the semiquantitative spectral counting method
and calculated the NSAF-value to analyze abundances of
proteins from three replicate samples [40-42] (additional
file 6). Many highly abundant proteins were extracellular
Overlap of protein identifications between the four most  comprehensive studies on CVF Figure 4
Overlap of protein identifications between the four 
most comprehensive studies on CVF. Orange and red 
areas contain proteins which are present in at least 3 out of 4 
studies and were included in the overlapping protein set (136 
proteins).
92
Shaw et al., 200728
Pereira et al., 200727 Dasari et al., 200724
This study
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proteins with an immunological function such as protein
S100A9 and S100A8, cystatin A/B, antileukoproteinase,
immunoglobins and elafin. Serum albumin and hemo-
globin alpha/beta were also abundant probably due to
plasma transudate.
Abundancy ranking of the 61 overlapping proteins
between our study and those from Dasari et al.[24] and
Pereira et al.[27] showed a very similar trend in all studies.
The slightly better fit between the latter two was not unex-
pected because both studies were carried out by the same
research group and thus the sample collection method,
patient physiology and LC-MS method were quite similar
(table 3). Nevertheless, we conclude that the relative
abundancy of the proteins identified in our study is simi-
lar to other studies even when other sample collection and
LC-MS methods are used.
Delineation of an overlapping protein set that is shared by 
various CVF proteomics studies
As mentioned before, we speculate that the CVF proteome
consists of two large parts: 1) a fixed set of proteins ("core
proteome") of which the composition does not vary and
which is usually present in the cervical-vaginal region irre-
spective of patient condition and the analytical methods
used and 2) a variable set of proteins from which abun-
dance is dependent on several physiological and experi-
mental factors. In fact, a similar situation has been seen in
human plasma where a substantial fraction of identifica-
tions from previous research papers (between 13 and
35%) wherein different sample preparations and identifi-
cation technologies were used, matched with a core data-
set established by the human plasma project[64]. We
compared the three most comprehensive CVF proteomics
studies [24,27,28] with our results and found an overlap-
Fold changes of functional categories between the total proteome and the overlapping protein set Figure 5
Fold changes of functional categories between the total proteome and the overlapping protein set. The total 
proteome (A) and the overlapping protein set (B) were classified into functional categories and the fold change of the different 
functional classes between these two sets was calculated as follows: percentage of a specific category of the overlapping pro-
tein set divided by the percentage of that category in the total proteome (C).
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ping protein set of 136 proteins. 120 proteins (35%) from
the 339 identified in our study were part of this overlap-
ping protein set (including 101 and 73 proteins from
samples A and B, respectively). These 120 proteins have
very divergent NSAF-values (from 32 to 2021; additional
file 6) indicating that they are present in different concen-
trations in the CVF and are not always highly abundant.
Also, the majority (60%, 80%, 87% and 94%) of the pro-
teins identified in the studies of respectively Tang et
al.[11], Venkataraman et al.[29], Di Quinzio et al.[26] and
Klein et al.[25] were present in this overlapping protein
set, confirming its mutual nature.
We then calculated the fold increase/decrease (in percent-
age) of functional and cellular localization categories (fig.
5 and fig. 6 respectively) in the overlapping protein set as
compared to the total set of proteins (826) identified in
all of the studies[11,24-29]. From this, we noticed signifi-
cant increases of the "immunity and defense" and "devel-
opmental processes" functional categories and of the
"extracellular region" and "cytoskeleton" cellular localiza-
tion categories. An increase of the "immunity and
defense" category was not unexpected since cervical-vagi-
nal immunity is an indispensable factor in preventing
infections of the lower female genital tract (see introduc-
tion). Indeed, proteins such as HNP, SLPI, lysozyme C,
azurocidin, etc. were frequently detected; many of them
even by all four studies (additional files 10 and 11). Since
all studies made use of samples of cervical-vaginal fluid,
and because many proteins from the innate immunity sys-
tem are present in the extracellular region, it was expected
that the portion of this latter category would also increase
in the overlapping protein set. The increases in the "devel-
opmental process" and "cytoskeleton" categories were less
Fold changes of cellular localization categories between the total proteome and the overlapping protein set Figure 6
Fold changes of cellular localization categories between the total proteome and the overlapping protein set. 
The total proteome (A) and the overlapping protein set (B) were classified according to the cellular localization (respectively A 
en B) and the fold change of the different functional classes between these two sets was calculated as follows: percentage of a 
specific category of the overlapping protein set divided by the percentage of that category in the total proteome (C).
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likely to occur. However, a closer look shows that a large
fraction (both 50%) of these categories consisted of pro-
teins that are part of the cornified envelope (e.g. small
proline rich proteins, periplakin, cystatin A, S100 pro-
teins, desmoplakin, enveloplakin, annexin I, etc). As men-
tioned before, since the lower female genital tract is lined
with a differentiated epithelial cell layer, the cornified
envelope is well developed[51] and parts of it may be
shed in the CVF.
We conclude that the use of colposcopy samples, com-
bined with the LC-MS platform described here, results in
a relatively high number of CVF protein identifications
(extracellular as well as intracellular). However, we are
aware of the fact that, due to the presence of acetic acid in
the colposcopy sample solution, local cell lysis may occur,
leading to the delivery of unwanted intracellular proteins
in the CVF. However, the comparison of our results with
other studies wherein cell lysis was minimized (Dasari et
al.[24] and Pereira et al.[27]) allowed us to distinguish
between correct and aberrant identifications. This is
because we expect identifications from unwanted intracel-
lular proteins to be more random. As such, these proteins
will not be picked up frequently and the chance of them
falling within the overlapping protein set will be drasti-
cally reduced. Indeed, during determination of the over-
lapping protein set, many intracellular proteins from all
of the studies were quickly filtered out since they did not
occur in at least three out of the four studies. As an exam-
ple, from the 40 nuclear proteins we identified in our
study, only 8 remained in the overlapping set.
In our study, we were able to identify 151 proteins which
were not identified in any other proteomics study on
human CVF so far[11,24-29]. Many of these are probably
the result of increased cellular lysis, due to the 5% acetic
acid present in the sample. On the other hand, the high
efficiency of the proteomics platform may have contrib-
uted to the unique identification of proteins which can be
expected to reside in the CVF. For instance, HBD-2 and
cathelicidin have never been identified in any previous
proteomics study, yet ELISA experiments show that these
peptides are definitely present in CVF[5,50]. One explana-
tion for this high number could be that characterization of
the CVF proteome has not reached saturation yet. Alterna-
tively, we suggest that every comprehensive proteomics
study on CVF will bring in proteins from the "core" as well
as the "variable" protein set whereby the chance of picking
up proteins from the former set is higher, hence the "core"
set will reach saturation faster. One must keep in mind
however, that not all proteins from the "core proteome"
have an expression level that allows identification. There-
fore, although this study gives an idea of the ratio between
the "core" and the "variable" set in CVF samples, exhaus-
tive lists of both proteomes must come from a collabora-
tive effort whereby statistically relevant numbers of
samples from well chosen patients are analyzed by several
proteomics strategies.
Conclusion
We showed here that routinely collected CVF colposcopy
samples, which are usually discarded, can be used for pro-
teomic studies on human CVF. In total, 339 proteins were
identified using different experimental setups. Compari-
son with other studies suggests that there is a large varia-
bility in terms of protein composition in CVF samples.
Therefore, two requirements need to be fulfilled when
using CVF samples for biomarker discovery and valida-
tion experiments: first, high numbers of samples need to
be analyzed in order to obtain statistically significant
results. Since the colposcopy samples used here can easily
be obtained in large quantities (samples from several hun-
dreds of patients can be collected over one year from the
colposcopy department) and from different centres, they
are well suited for such extensive experiments. Second, the
lack of a good internal standard makes comparison and
quantitative analysis of CVF samples difficult. For this rea-
son we determined an overlapping protein set which we
consider to be a first step towards the delineation of a CVF
"core proteome". Although more studies need to be exe-
cuted on CVF samples before the final determination of
this "core proteome" can be obtained, this proteome has
likely a lower variability and may be proven useful as a ref-
erence proteome for normalization during analysis of the
different samples with different proteomics platforms.
Finally, among the 339 proteins identified in this study,
151 were not previously identified in any proteomics
study on human CVF. Among those were proteins which
are present in the lower female genital tract, such as HBD-
2 and cathelicidin, two proteins that play an important
role in the innate immunity of the cervicovagina. All
together, our results suggest that the colposcopy samples
in combination with the proteomics platform applied
here can be used for comprehensive proteomics studies
on CVF.
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